Abeje A. Silte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abeje A. Silte has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Yan Zhang
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, Virginia 23298, United States
4 shared publications - Balaji S. Kale
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, Virginia 23298, United States
3 shared publications Neha Upadhyay
Department of Medicinal Chemistry, School of Pharmacy
3 shared publications- Piyusha P. Pagare
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, Virginia 23298, United States
3 shared publications Rui Lyu
Department of Medicinal Chemistry, School of Pharmacy
3 shared publicationsWilliam L. Dewey
Department of Pharmacology and Toxicology
3 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16658-16676
Landscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological Profiling
The surge in ultrapotent synthetic opioids has intensified the need for new chemical strategies for modulating the mu-opioid receptor (MOR). In this study, nitazene scaffold, a chemically distinct and underexplored chemotype, was utilized as an underexplored framework for MOR modulation. Structure-activity relationship studies were conducted through modifications at three key positions of the nitazene core and evaluated for MOR binding, in vitro functional, and in vivo behavioral activities. Among them, compound 26 significantly blocked the effects of synthetic opioids, including fentanyl and etonitazene. It also demonstrated affinity and selectivity for MOR and exhibited favorable metabolic stability and CNS permeability. Molecular modeling studies provided structural insights into potential binding modes of these ligands. This work expands the chemical space for opioid receptor ligands and provides a proof-of-concept that the nitazene core is chemically tunable for MOR functional modulation, highlighting nitazenes as a promising platform for future therapeutic exploration.
- 6 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16658-16676
Open AccessLandscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological Profiling
The surge in ultrapotent synthetic opioids has intensified the need for new chemical strategies for modulating the mu-opioid receptor (MOR). In this study, nitazene scaffold, a chemically distinct and underexplored chemotype, was utilized as an underexplored framework for MOR modulation. Structure-activity relationship studies were conducted through modifications at three key positions of the nitazene core and evaluated for MOR binding, in vitro functional, and in vivo behavioral activities. Among them, compound 26 significantly blocked the effects of synthetic opioids, including fentanyl and etonitazene. It also demonstrated affinity and selectivity for MOR and exhibited favorable metabolic stability and CNS permeability. Molecular modeling studies provided structural insights into potential binding modes of these ligands. This work expands the chemical space for opioid receptor ligands and provides a proof-of-concept that the nitazene core is chemically tunable for MOR functional modulation, highlighting nitazenes as a promising platform for future therapeutic exploration.
- Open Access
- 30 April 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (10) , 1888-1908
Structural Determinants of μ-Opioid Receptor Antagonism and Respiratory Liability in Phenylfentanyl Analogues
The μ-opioid receptor (MOR) plays a key role in opioid addiction and fentanyl-induced respiratory depression. Phenylfentanyl, previously reported as a MOR antagonist, paradoxically induces respiratory depression in vivo, revealing a dissociation between receptor antagonism and respiratory liability within this scaffold. To interrogate structural determinants underlying this activity profile, phenylfentanyl was redesigned through systematic modification of the acyl chain, N-alkyl group, and core ring scaffold, including exploration of a 6,6-ring extension to probe the MOR binding space. Seventy-eight compounds were synthesized and evaluated. The 6,6-ring series exhibited markedly reduced MOR activity relative to the 6-membered core analogues, likely due to suboptimal pharmacophore spacing. Among these, compound 5 demonstrated solid MOR antagonist activity, effectively blocking morphine- and fentanyl-induced antinociception in vivo and showing greater potency than phenylfentanyl in vitro. Importantly, compound 5 did not induce respiratory depression at the tested dose, indicating a lack of intrinsic respiratory liability. These findings delineate structural features governing MOR antagonism and respiratory effects within a fentanyl-derived scaffold.
- 30 April 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (10) , 1888-1908
Open AccessStructural Determinants of μ-Opioid Receptor Antagonism and Respiratory Liability in Phenylfentanyl Analogues
The μ-opioid receptor (MOR) plays a key role in opioid addiction and fentanyl-induced respiratory depression. Phenylfentanyl, previously reported as a MOR antagonist, paradoxically induces respiratory depression in vivo, revealing a dissociation between receptor antagonism and respiratory liability within this scaffold. To interrogate structural determinants underlying this activity profile, phenylfentanyl was redesigned through systematic modification of the acyl chain, N-alkyl group, and core ring scaffold, including exploration of a 6,6-ring extension to probe the MOR binding space. Seventy-eight compounds were synthesized and evaluated. The 6,6-ring series exhibited markedly reduced MOR activity relative to the 6-membered core analogues, likely due to suboptimal pharmacophore spacing. Among these, compound 5 demonstrated solid MOR antagonist activity, effectively blocking morphine- and fentanyl-induced antinociception in vivo and showing greater potency than phenylfentanyl in vitro. Importantly, compound 5 did not induce respiratory depression at the tested dose, indicating a lack of intrinsic respiratory liability. These findings delineate structural features governing MOR antagonism and respiratory effects within a fentanyl-derived scaffold.
- 27 November 2025
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 150, 110206
Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes
- 27 November 2025
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 150, 110206
Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes
- Open Access
- 3 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 22170-22195
Design, Syntheses, and Pharmacological Evaluations of Core Ring Expanded Fentanyl Analogues as Potential Counteracting Agents Against Fentanyl Induced Respiratory Depression
The escalating synthetic opioid crisis necessitates novel treatments, especially for fentanyl overdose. This study presents 84 ring-expanded fentanyl analogs, replacing its piperidine core with 4-azepane and 5-azocane structures. In vivo antagonism studies identified 15 compounds that effectively blocked synthetic opioid antinociception. Further dose-response analysis identified four potent antagonists (16, 46, 53, and 69) against both fentanyl and morphine. Notably, Compound 53 demonstrated the highest potency with AD50 of 2.02 mg/kg against morphine and 4.02 mg/kg against fentanyl. Compound 53 exhibits a favorable pharmacokinetic profile, including moderate human metabolic stability, low efflux, and efficient, sustained CNS penetration, making it a promising centrally acting MOR antagonist candidate. Significantly, whole-body plethysmography confirmed that compound 53 reversed fentanyl-induced respiratory depression. These results suggest that expanding the core ring structure of fentanyl is a promising strategy to develop potent mu opioid receptor antagonists to inhibit both antinociception and respiratory depression offering potential solutions to fentanyl overdose.
- 3 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 22170-22195
Open AccessDesign, Syntheses, and Pharmacological Evaluations of Core Ring Expanded Fentanyl Analogues as Potential Counteracting Agents Against Fentanyl Induced Respiratory Depression
The escalating synthetic opioid crisis necessitates novel treatments, especially for fentanyl overdose. This study presents 84 ring-expanded fentanyl analogs, replacing its piperidine core with 4-azepane and 5-azocane structures. In vivo antagonism studies identified 15 compounds that effectively blocked synthetic opioid antinociception. Further dose-response analysis identified four potent antagonists (16, 46, 53, and 69) against both fentanyl and morphine. Notably, Compound 53 demonstrated the highest potency with AD50 of 2.02 mg/kg against morphine and 4.02 mg/kg against fentanyl. Compound 53 exhibits a favorable pharmacokinetic profile, including moderate human metabolic stability, low efflux, and efficient, sustained CNS penetration, making it a promising centrally acting MOR antagonist candidate. Significantly, whole-body plethysmography confirmed that compound 53 reversed fentanyl-induced respiratory depression. These results suggest that expanding the core ring structure of fentanyl is a promising strategy to develop potent mu opioid receptor antagonists to inhibit both antinociception and respiratory depression offering potential solutions to fentanyl overdose.